Abstract
Mucosal drug delivery is considered as a convenient, mild and safe route, especially for the treatment of chronic diseases. In general, mucosal routes include buccal, ocular, intranasal, pulmonary, vaginal and oral delivery. To increase the efficiency of mucosal delivery, nanocarriers have been extensively explored, of which lipidbased nanocarriers attract much attention due to their great biocompatibility, cell membrane affinity and other excellent physicochemical properties by using different kinds of lipids. However, the effectiveness of lipid-based nanocarriers is limited by numerous in vivo physiological barriers (e.g. chemical environment, mucus and epithelium) in tracts or cavities. Herein, modification strategies of these nanocarriers are widely investigated and show great improvement of drug bioavailability. The aim of this review is to introduce applications of lipid-based nanocarriers in different mucosal routes and discuss typical modification strategies.
Keywords: Lipid-based nanocarriers, modification strategies, mucosal delivery, absorption barriers.
Current Pharmaceutical Design
Title:Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Volume: 21 Issue: 36
Author(s): Lei Wu, Min Liu, Xi Zhu, Wei Shan and Yuan Huang
Affiliation:
Keywords: Lipid-based nanocarriers, modification strategies, mucosal delivery, absorption barriers.
Abstract: Mucosal drug delivery is considered as a convenient, mild and safe route, especially for the treatment of chronic diseases. In general, mucosal routes include buccal, ocular, intranasal, pulmonary, vaginal and oral delivery. To increase the efficiency of mucosal delivery, nanocarriers have been extensively explored, of which lipidbased nanocarriers attract much attention due to their great biocompatibility, cell membrane affinity and other excellent physicochemical properties by using different kinds of lipids. However, the effectiveness of lipid-based nanocarriers is limited by numerous in vivo physiological barriers (e.g. chemical environment, mucus and epithelium) in tracts or cavities. Herein, modification strategies of these nanocarriers are widely investigated and show great improvement of drug bioavailability. The aim of this review is to introduce applications of lipid-based nanocarriers in different mucosal routes and discuss typical modification strategies.
Export Options
About this article
Cite this article as:
Wu Lei, Liu Min, Zhu Xi, Shan Wei and Huang Yuan, Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery, Current Pharmaceutical Design 2015; 21 (36) . https://dx.doi.org/10.2174/1381612821666150923103000
DOI https://dx.doi.org/10.2174/1381612821666150923103000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Current Drug Delivery Epidemiology of Septic Acute Kidney Injury
Current Drug Targets Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Experimental Model Considerations for the Study of Protein-Energy Malnutrition Co-Existing with Ischemic Brain Injury
Current Neurovascular Research Obstetrical Hemorrhage Review
Current Women`s Health Reviews Exercise as Treatment for Neuropathy in the Setting of Diabetes and Prediabetic Metabolic Syndrome: A Review of Animal Models and Human Trials
Current Diabetes Reviews A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets Synthesis of 5-Arylidene Barbiturates: A Novel Class of DPPH Radical Scavengers
Letters in Drug Design & Discovery Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Relationship Between Inflammation and the Anticoagulant Pathway: The Emerging Role of Endothelial Nitric Oxide Synthase (eNOS)
Current Pharmaceutical Design Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry Red Wine, Arterial Stiffness and Central Hemodynamics
Current Pharmaceutical Design Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse
Current Medicinal Chemistry - Central Nervous System Agents Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Does the Association Between Anxiety and Parkinsons Disease Really Exist? A Literature Review
Current Psychiatry Reviews